CN109172722A - 一种治疗痤疮的组合物及其应用 - Google Patents
一种治疗痤疮的组合物及其应用 Download PDFInfo
- Publication number
- CN109172722A CN109172722A CN201811426391.8A CN201811426391A CN109172722A CN 109172722 A CN109172722 A CN 109172722A CN 201811426391 A CN201811426391 A CN 201811426391A CN 109172722 A CN109172722 A CN 109172722A
- Authority
- CN
- China
- Prior art keywords
- parts
- acne
- radix
- composition
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 98
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 87
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 238000011282 treatment Methods 0.000 claims abstract description 52
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims abstract description 44
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims abstract description 25
- 229960005280 isotretinoin Drugs 0.000 claims abstract description 25
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 22
- 229960003276 erythromycin Drugs 0.000 claims abstract description 22
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 22
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 22
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 22
- 229930003231 vitamin Natural products 0.000 claims abstract description 18
- 235000013343 vitamin Nutrition 0.000 claims abstract description 18
- 239000011782 vitamin Substances 0.000 claims abstract description 18
- 229940088594 vitamin Drugs 0.000 claims abstract description 18
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 17
- 235000002991 Coptis groenlandica Nutrition 0.000 claims description 18
- 244000247747 Coptis groenlandica Species 0.000 claims description 18
- 241000209020 Cornus Species 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 17
- SHGAZHPCJJPHSC-UHFFFAOYSA-N Panrexin Chemical compound OC(=O)C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-UHFFFAOYSA-N 0.000 claims description 10
- 241001116389 Aloe Species 0.000 claims description 9
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims description 9
- 244000061520 Angelica archangelica Species 0.000 claims description 9
- 241000205585 Aquilegia canadensis Species 0.000 claims description 9
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims description 9
- 235000003097 Artemisia absinthium Nutrition 0.000 claims description 9
- 240000001851 Artemisia dracunculus Species 0.000 claims description 9
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims description 9
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 9
- 241000208671 Campanulaceae Species 0.000 claims description 9
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 9
- 244000020518 Carthamus tinctorius Species 0.000 claims description 9
- 241000931705 Cicada Species 0.000 claims description 9
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 9
- QQILFGKZUJYXGS-UHFFFAOYSA-N Indigo dye Chemical compound C1=CC=C2C(=O)C(C3=C(C4=CC=CC=C4N3)O)=NC2=C1 QQILFGKZUJYXGS-UHFFFAOYSA-N 0.000 claims description 9
- 240000005001 Paeonia suffruticosa Species 0.000 claims description 9
- 235000003889 Paeonia suffruticosa Nutrition 0.000 claims description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 9
- 235000011399 aloe vera Nutrition 0.000 claims description 9
- 239000001138 artemisia absinthium Substances 0.000 claims description 9
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 9
- 241000405414 Rehmannia Species 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 8
- 241000882890 Renova Species 0.000 claims description 5
- 235000019508 mustard seed Nutrition 0.000 claims description 5
- 229940059527 renova Drugs 0.000 claims description 5
- 229940002683 retin-a Drugs 0.000 claims description 5
- 210000000582 semen Anatomy 0.000 claims description 4
- 239000012752 auxiliary agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 64
- 229940079593 drug Drugs 0.000 abstract description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 27
- 201000010099 disease Diseases 0.000 abstract description 23
- 238000002360 preparation method Methods 0.000 abstract description 10
- 206010067484 Adverse reaction Diseases 0.000 abstract description 5
- 230000006838 adverse reaction Effects 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000000857 drug effect Effects 0.000 abstract description 3
- 230000035876 healing Effects 0.000 abstract description 2
- 238000012153 long-term therapy Methods 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 24
- 206010033733 Papule Diseases 0.000 description 22
- 210000003491 skin Anatomy 0.000 description 19
- 239000008280 blood Substances 0.000 description 13
- 210000004369 blood Anatomy 0.000 description 13
- 210000004209 hair Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 230000001815 facial effect Effects 0.000 description 10
- 210000000115 thoracic cavity Anatomy 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 208000012641 Pigmentation disease Diseases 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000003907 kidney function Effects 0.000 description 9
- 230000003908 liver function Effects 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 230000019612 pigmentation Effects 0.000 description 9
- 239000002674 ointment Substances 0.000 description 8
- 239000000825 pharmaceutical preparation Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 231100000241 scar Toxicity 0.000 description 7
- 102000004420 Creatine Kinase Human genes 0.000 description 6
- 108010042126 Creatine kinase Proteins 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 210000001061 forehead Anatomy 0.000 description 6
- 210000003128 head Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 210000002374 sebum Anatomy 0.000 description 5
- 208000005189 Embolism Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 210000001732 sebaceous gland Anatomy 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 208000000260 Warts Diseases 0.000 description 3
- 206010000269 abscess Diseases 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000027744 congestion Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000003349 gelling agent Substances 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 229960001727 tretinoin Drugs 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 206010011732 Cyst Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010061926 Purulence Diseases 0.000 description 2
- 206010039792 Seborrhoea Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- -1 nitro glyoxaline Chemical compound 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010000501 Acne conglobata Diseases 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical class C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010013709 Drug ineffective Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021925 Inferiority complex Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000186429 Propionibacterium Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000021945 Tendon injury Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000021185 dessert Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 102000006255 nuclear receptors Human genes 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- XCRBXWCUXJNEFX-UHFFFAOYSA-N peroxybenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1 XCRBXWCUXJNEFX-UHFFFAOYSA-N 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000003859 smegma Anatomy 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960000565 tazarotene Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
- A61K36/195—Strobilanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
- A61K36/315—Isatis, e.g. Dyer's woad
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Insects & Arthropods (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Husbandry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明属于药物制剂技术领域,具体涉及一种治疗痤疮的组合物及其应用。所述一种治疗痤疮的组合物,按照重量计算含有以下组份:异维A酸10‑30份、红霉素110‑125份、维生素B6 10‑30份、葡萄糖酸锌60‑80份。所述的治疗痤疮的组合物在制备的治疗痤疮的药物具有小剂量,长疗程,不良反应少的优点,患者依从性好,能坚持按疗程服用,从而使病因得以持续清除,药效能持久发挥作用,故愈后不易复发,为广大饱受痤疮困扰的患者带来了福音。
Description
技术领域
本发明属于药物制剂技术领域,具体涉及一种治疗痤疮的组合物及其应用。
背景技术
痤疮(俗称青春痘),随着人们生活水平的提高,生活节奏加快,食谱改变(过于辛辣,油腻,甜点等食品摄入过多)作息不规律,环境气候变化。加之体内激素失调,遗传等多种致病因素、作用于人体头面,胸背皮肤皮脂腺,使腺体分泌增加,角质栓塞,排出不畅,并发痤疮丙酸杆菌感染,从而导致本病发生。
概念,痤疮,是毛囊皮脂腺单位的一种慢性炎症性皮肤病,主要好发于青春期,故俗称(青春痘),男女均可患病,常有头面皮脂溢出,多油腻现象。但35一50岁人群亦可少有发病。多发于人体头面,颈部,胸背等部位,早期丘疹,白头,黑头,粉刺,中期逐渐形成脓疱,结节。晚期皮肤严重受损,形成持续性色素沉着,痘坑,痘印,瘢痕等不可逆皮肤损害。
据临床资料显示,本病发病率呈逐年上升趋势。在治疗上,本病目前用单纯的中药,西药,外擦药,激光等疗法常规治疗,治愈率低,多易复发,呈顽固病例表现,疗效不尽人意。且随着病程延长,久治不愈,继续损伤皮肤,重者可在面部留下痘印,痘疤,持久性皮脂色素沉着等不可逆的皮肤容貌伤害。加之面部痤疮病损持续不愈或愈后留下疤痕等因素,给患者就业,工作,生活,学习,择偶带来诸多不便。同时自卑心理也给患者身心健康带来极大伤害。
目前西医西药在治疗痤疮方面主要存在的缺点为:1)单纯改变饮食及作息习惯反作为一般治疗,但多无显著效果;2)抗生素多以四环素类及大环内脂类或硝基咪唑类为主,它们的共缺点是用药剂量大,疗程长,易耐药,易损伤肝肾功能,胃肠道,亦可损害人体造血系统,长期应用可致菌群失调(二重感染)等;3)维生素类单用疗效多不明显,仅作辅助治疗用药;4)维A酸类口服制剂,临床常用剂量过大,疗程过长,常见不良反应为皮肤干燥,唇干裂,脱屑,瘙痒,疼痛,皮疹,还可出现继发感染,横纹肌融解,肌腱损伤,等症;5)使用一些内分泌制剂如①雌性激素疗程过长有血栓栓塞等风险,女性患者可致月经紊乱等;②糖皮质激素用量过大或疗程过长可致胃溃疡,胃出血,感染加重,骨质疏松,骨折等;③抗雄激素类药,安体舒通,甲氰咪胍长期应用可致血钾增高等,外用药抗生素类,长期应用可致皮肤二重感染,刺激皮肤,皮肤过敏,耐药等;④硫磺乳膏类药单用疗效不太明显;⑤过氧苯甲酰类药疗效尚可,需长期应用方可奏效,但皮肤刺激性大,易致皮肤烧灼,疼痛,红斑,脱皮,亦可致毛发变白,患者依从性差,不能坚持用药也是其缺点;⑥维A酸类外擦药的缺点与过氧苯甲酰大致相同。除开西医西药,还有医美方向的光疗,面膜,等仅作为一般疗法,单用对中重度痤疮多效果不佳,需加入口服药等治法方能才能有所疗效。
目前中医中药缺点在治疗痤疮方面主要存在的缺点为:1)内服药汤剂疗程一般较长,煎煮耗时,费力,短期难以奏效;2)服药时不能定时,定量,体内药效难以恒时释放,有效浓度分布不均;3)临床疗效缺乏循证医学证据,多凭经验用药;4)因携带服用不便,患者依从性差,不能坚持长期用药等因素,故疗效不尽人意;5)中医外用药,亦多属传统中医经验用药,亦缺乏临床数据及标准,对部分有效,且外用中药治疗本病多只能临床缓解,极难治愈。
鉴于本病发病率高,治愈率低,病程长,易复发,愈后易留疤痕等特点,以及针对上述中西医的各自优势与不足,本发明申请人严谨地将中西医结合,提出了一种新的有效治疗痤疮的组合物,经多年临床门诊治疗证明所述组合物可治疗各型痤疮,尤其对中重度痤疮,或顽固不愈的病例疗效可靠。
发明内容
有鉴于此,本发明的目的之一在于提供一种治疗痤疮的组合物,该组合物是根据现有西医医学基础理论,针对该病病理,皮肤皮脂腺腺体分泌过多,角质栓塞,痤疮丙酸杆菌感染而致皮脂损的特性,以及中医医学病理研究本病乃外在风邪,湿热,瘀毒等邪入肌肤,留于血分,煎脓化腐而致本病的特性所提出。
为实现上述目的,本发明采用以下技术方案:
一种治疗痤疮的组合物,按照重量计算含有以下组份:异维A酸10-30份、红霉素110-125份、维生素B6 10-30份、葡萄糖酸锌60-80份。
异维A酸具有缩小皮脂腺组织,抑制皮脂腺活性,减少皮脂腺分沁,减轻上皮细胞异常角化及毛囊皮脂腺的栓塞,并可抑制痤疮丙酸杆菌的生长繁殖为主要药物。近年来相关研究表明本药有非特异消炎免疫调节作用,所述治疗痤疮的组合物可调控与痤疮发病机制相关的炎症免疫介质以及选择性结合维A酸核受体而发挥治疗作用。
红霉素可直接抑杀痤疮丙酸杆菌,葡萄球菌等致病菌,据相关药理数据显示,该药另有非特异消炎及抗免疫作用,可间接保护皮脂腺及其组织,维护腺体上皮细胞的正常角化及稳定性而发挥治疗作用。
维生素B6临床上可用于治疗脂性皮炎等皮脂溢出性疾病,其作用机理有抑制和调节皮脂分泌作用而发挥作用。
葡萄糖酸锌,在该病治疗中具有减轻皮脂腺分泌,促进受损腺管上皮胞修复有积极作用。
进一步的,所述的一种治疗痤疮的组合物,按照重量计算由以下组份组成:异维A酸10-30份、红霉素110-125份、维生素B6 10-30份、葡萄糖酸锌60-80份、水牛角浓缩粉40-50份、连翘130-140份、青黛40-50份、黄连10-15份、炒牛蒡子110-120份、玄参130-140份、地黄100-120份、桔梗100-120份、芒硝10-15份、赤芍100-120份、甘草130-140份。
优选的,按照重量计算由以下组份组成:异维A酸20-30份、红霉素120-125份、维生素B6 20-30份、葡萄糖酸锌65-75份、水牛角浓缩粉40-45份、连翘130-135份、青黛40-45份、黄连12-15份、炒牛蒡子110-115份、玄参130-135份、地黄100-110份、桔梗110-120份、芒硝12-15份、赤芍110-120份、甘草130-135份。
更优选的,按照重量计算由以下组份组成:异维A酸20份、红霉素125份、维生素B620份、葡萄糖酸锌70份、水牛角浓缩粉45份、连翘135份、青黛45份、黄连12份、炒牛蒡子115份、玄参135份、地黄110份、桔梗116份、芒硝12份、赤芍116份、甘草135份。
进一步的,所述的一种治疗痤疮的组合物,按照重量计算由以下组份组成:异维A酸10-30份、红霉素110-125份、维生素B6 10-30份、葡萄糖酸锌60-80份、茵陈120-140份,水牛角粉100-120份,生地100-120份,丹皮100-110份,玄参80-90份,黄连60-80份,金银花80-90份,芦荟20-30份,蝉蜕40-50份,当归60-80份,红花40-50份,白芷80-90份,白芥子40-50份、珍珠80-90份。
优选的,按照重量计算由以下组份组成:异维A酸20-30份、红霉素120-125份、维生素B6 20-30份、葡萄糖酸锌65-75份、茵陈130-140份,水牛角粉110-120份,生地110-120份,丹皮100-105份,玄参85-90份,黄连60-70份,金银花85-90份,芦荟25-30份,蝉蜕45-50份,当归60-70份,红花45-50份,白芷85-90份,白芥子45-50份、珍珠85-90份。
更优选的,按照重量计算由以下组份组成:异维A酸20份、红霉素125份、维生素B620份、葡萄糖酸锌70份、茵陈135份,水牛角粉111份,生地111份,丹皮101份,玄参85份,黄连67份,金银花85份,芦荟25份,蝉蜕45份,当归67份,红花45份,白芷85份,白芥子45份、珍珠85份。
本发明目的之二在于提供一种所述治疗痤疮的组合物的应用,具体为在制备治疗痤疮药物中的应用。本发明申请人行医二十多年,对中西医理论和病理知识甚为了解,所述治疗痤疮的组合物经10余年的临床验证,确认所述治疗痤疮的组合物具有治愈率高,安全性高,不良反应少,依从性好,不易复发等优点。
为实现上述目的,本发明采用以下方案:
所述治疗痤疮药物可以为任意药学可接受剂型。
进一步的,所述治疗痤疮药物还包括药学可接受载体和/或助剂。
所述药学可接受剂型包括本发明的中药组合物以及可选的一种或多种药学上可接受的载体、稀释剂或赋形剂并在上述制备过程中合适的步骤加入。本发明所使用的术语“药学上可接受的”是指这样的化合物、原料、组合物和/或剂型,它们在合理医学判断的范围内,适用于与患者组织接触而无过度毒性、刺激性、变态反应或与合理的利益/风险比相对称的其他问题和并发症,并有效用于既定用途。
药物制剂适于通过任何合适的途径给药,例如通过口服(包括口腔或舌下)、直肠、鼻、局部(包括口腔、舌下或经皮)、阴道或胃肠外(包括皮下、皮内、肌内、关节内、滑膜内、胸骨内、鞘内、病灶内、静脉内或者真皮下注射或输注)途径。可按药剂学领域的任何已知方法制备这类制剂,例如通过将活性成分与载体或赋形剂混合。优选口服给药、局部给药或注射给药。适于口服给药的药物制剂按独立的单位提供,例如水性或非水性液体中的溶液剂或混悬剂;胶囊剂或片剂;散剂或颗粒剂;可食用泡沫制剂或起泡制剂等。
举例来说,对于以片剂或胶囊剂形式的口服给药,活性药物组分可与药学上可接受的口服无毒惰性载体(例如乙醇、甘油、水等)相混合。通过将化合物粉碎成合适的微细尺寸,并与被同样粉碎的药用载体(例如淀粉或甘露醇等可食用的糖类)混匀来制备散剂。还可存在矫味剂、防腐剂、分散剂和着色剂。通过制备如上所述的粉状混合物,并装填到成形的明胶壳内,来制备胶囊剂。在装填操作之前,可将助流剂和润滑剂(例如胶态二氧化硅、滑石粉、硬脂酸镁、硬脂酸钙或固态聚乙二醇)加到粉状混合物中。还可加入当服下胶囊剂时将改进药物可利用性的崩解剂或增溶剂(例如琼脂、碳酸钙或碳酸钠)。
此外需要或必需时,也可将合适的粘合剂、润滑剂、崩解剂和着色剂掺到混合物中。合适的粘合剂包括淀粉、明胶、天然糖(例如葡萄糖或β-乳糖)、玉米甜味剂、天然和合成树胶(例如阿拉伯树胶、西黄蓍胶或藻酸钠)、羧甲基纤维素、聚乙二醇等。用于这些剂型的润滑剂包括油酸钠、氯化钠等。
崩解剂包括但并不限于淀粉、甲基纤维素、琼脂、皂土、黄原胶等。例如,通过制成粉状混合物,制粒或预压片,加入润滑剂和崩解剂,压制成片,从而制成片剂。将适当粉碎的化合物与如上述所述的稀释剂或基料、任选与粘合剂(例如羧甲基纤维素、藻酸盐、明胶或聚乙烯吡咯烷酮)、溶解阻止剂(例如石蜡)、吸收加速剂(季盐)和/或吸收剂(例如皂土、高岭土或磷酸二钙)混合,来制备粉状混合物。可用粘合剂(例如糖浆、淀粉浆、阿拉伯胶浆或纤维素材料或聚合材料溶液)润湿后加压过筛,将粉状混合物制粒。制粒的一个替代方法是,可将粉状混合物通过压片机,结果是将形成不佳的团块再击碎制成颗粒。可通过加入硬脂酸、硬脂酸盐,滑石粉或矿物油使颗粒润滑以防止粘到压片机的冲模上。然后将经润滑的混合物压制成片。本发明内容的化合物还可与自由流动的惰性载体混合,无需通过制粒或预压片步骤便可压制成片。可提供透明或不透明的由虫胶密封衣、糖衣或聚合材料衣和蜡质抛光衣组成的保护性包衣材料。可将染料加到这些包衣材料中以区分不同的单位剂量。
口服液体制剂例如溶液剂、糖浆剂和酏剂可以剂量单位形式制备,从而给定量含有预定量的化合物。糖浆剂可通过将化合物溶于适当调味的水溶液中来制备,而酏剂可通过使用无毒溶媒来制备。还可加入防腐剂、矫味添加剂(例如薄荷油或天然甜味剂或糖精或其他人造甜味剂)等。
适于经皮给药的药物制剂可作为离散的贴剂以在长时间内保持与接受者表皮密切接触。例如,活性成分可由通过离子导入贴剂递药,通常可参见PharmaceuticalResearch1986,3(6),318。
适于局部给药的药物制剂可制成软膏剂、乳膏剂、混悬剂、洗剂、散剂、溶液剂、糊剂、凝胶剂、喷雾剂、气雾剂、油制剂或透皮贴剂。适于经鼻给药的药物制剂(其中载体为固体)包括粒径为例如20-500微米范围的粗粉剂,通过以鼻吸方式给药,即通过鼻通道从接近鼻子的粗粉剂容器中快速吸入。其中载体为液体、适于作为鼻腔喷雾剂或滴鼻剂给药的合适制剂包括活性成分的水性溶液剂或油性溶液剂。
适于通过吸入给药的药物制剂包括微细粒子粉剂或细雾剂,可用不同类型计量的剂量压缩气溶胶、雾化吸入器、吹入器或其他事宜递送气溶胶喷雾剂的装置中制备。适于胃肠外给药的药物制剂包括水性和非水性无菌注射溶液剂及水性和非水性无菌混悬剂,水性和非水性无菌注射溶液剂可含有抗氧化剂、缓冲剂、抑菌剂和使所述制剂与待接受者血液等渗的溶质。制剂可以单位剂量或多剂量容器提供,例如密封的安凯和小瓶,并可保存在冷冻干燥(冻干)条件下,只需在临用前加入无菌液体载体,例如注射用水。临用时配置的注射溶液剂可由无菌粉针剂、颗粒剂和片剂制备。
药物制剂可呈单位剂型,每个单位剂量含有预定量的活性成分。给药法可用作长期或短期疗法。与载体材料混合以制备单一剂型的活性成分的量将根据待治疗的疾病、疾病的严重程度、给药时间、给药途径、所用化合物的排泄速率、治疗时间和患者年龄、性别、体重和情况而改变。优选的单位剂型是含有上述活性成分的日剂量或分剂量或其适宜分数的单位剂型。可用显然低于化合物最佳剂量的小剂量开始治疗。此后,以较小的增量来加大剂量直到在这种情况下达到最佳效果。一般而言,最理想地给予化合物的浓度水平是通常可在抗病毒方面提供有效结果而又不至于引起任何有害或有毒的副作用。
本发明的有益效果在于:1)本发明提供的一种治疗痤疮的组合物,所述组合物制备的治疗痤疮的药物具有小剂量,长疗程,不良反应少的优点,患者依从性好,能坚持按疗程服用,从而使病因得以持续清除,药效能持久发挥作用,故愈后不易复发;2)所述治疗痤疮的药物属于中西医结合联合用药,克服了中西药单独用药的缺点,且经发明申请人临床验证十年余年的临床验证,未有一例发生严重不良事件,且92%以上三年内未见复发,因此其具有治愈率高,安全性高,不良反应少,不易复发的优点,为广大饱受痤疮困扰的患者带来了福音。
具体实施方式
所举实施例是为了更好地对本发明进行说明,但并不是本发明的内容仅局限于所举实施例。所以熟悉本领域的技术人员根据上述发明内容对实施方案进行非本质的改进和调整,仍属于本发明的保护范围。
实施例1
一种治疗痤疮的组合物,按照重量计算由以下组份组成:异维A酸10份、红霉素110份、维生素B6 10份、葡萄糖酸锌60份、水牛角浓缩粉40份、连翘130份、青黛40份、黄连10份、炒牛蒡子110份、玄参130份、地黄100份、桔梗100份、芒硝10份、赤芍100份、甘草130份。
实施例2
一种治疗痤疮的组合物,按照重量计算由以下组份组成:异维A酸20份、红霉素118份、维生素B6 20份、葡萄糖酸锌70份、水牛角浓缩粉45份、连翘135份、青黛45份、黄连13份、炒牛蒡子115份、玄参135份、地黄115份、桔梗110份、芒硝13份、赤芍110份、甘草135份。
实施例3
一种治疗痤疮的组合物,按照重量计算由以下组份组成:异维A酸30份、红霉素125份、维生素B6 30份、葡萄糖酸锌80份、水牛角浓缩粉50份、连翘140份、青黛50份、黄连15份、炒牛蒡子120份、玄参140份、地黄120份、桔梗120份、芒硝15份、赤芍120份、甘草140份。
实施例4
一种治疗痤疮的组合物,按照重量计算由以下组份组成:异维A酸10份、红霉素110份、维生素B6 10份、葡萄糖酸锌60份、茵陈120份,水牛角粉100份,生地100份,丹皮100份,玄参80份,黄连60份,金银花80份,芦荟20份,蝉蜕40份,当归60份,红花40份,白芷80份,白芥子40份、珍珠80份。
实施例5
一种治疗痤疮的组合物,按照重量计算由以下组份组成:异维A酸20份、红霉素118份、维生素B6 20份、葡萄糖酸锌70份、茵陈130份,水牛角粉110份,生地110份,丹皮105份,玄参85份,黄连70份,金银花70份,芦荟25份,蝉蜕45份,当归70份,红花45份,白芷85份,白芥子45份、珍珠85份。
实施例6
一种治疗痤疮的组合物,按照重量计算由以下组份组成:异维A酸30份、红霉素125份、维生素B6 30份、葡萄糖酸锌80份、茵陈140份,水牛角粉120份,生地120份,丹皮110份,玄参90份,黄连80份,金银花90份,芦荟30份,蝉蜕50份,当归80份,红花50份,白芷90份,白芥子50份、珍珠90份。
实施例7
将实施例1-6所述的治疗痤疮的组合物依次制备成相应的软膏、丸剂、粉剂、片剂、口服溶液、凝胶剂。
病例1
患者唐XX,女,36岁,2015于年3月5日因面部满布丘疹,脓疱,囊肿反复五年逐渐加重前来就诊,患者五年前面部,前额,鼻翼周围散在丘疹,未在意,随后一年逐年加重,丘疹颗粒增多,变大,部分顶部夹有黑头,白头脓栓。用手挤后破溃流出脓栓后部门可自愈,另有部分并发感染则形成脓肿,则伴有红肿疼痛等症,期间曾间断服用中药(清热解毒,泻火类),西药(经某医院皮肤科连续治疗三月余),药名不祥,疗效不明显,反复发作。乃至病情逐年加重,就诊时,面颈胸背满布红色丘疹,皮肤色素沉着,不痒不痛,部分脓肿,有波动感,或囊肿形成。或夹杂红肿疼痛,大者1一2厘米以上,或太阳晒后有痒痛症状,面部己留下部分痘印痘坑,
经诊断为聚合性痤疮,采用实施例1所制备的软膏涂于病灶部位,用药1个月,嘱患者服药期间不宜备孕,须停药3个月后方可怀孕。避免阳光及紫外线直射,
4月5日复诊,面,颈,胸背丘疹己明显减少,白头,黑头亦减少,皮肤颜色有所恢复,脓肿,囊肿稍小,面部皮肤脱屑,唇干脱皮,余无不适,一个月后查验血常规,心电图,肝肾等功能指标,均无异常。因此此治疗痤疮的软膏疗效己显,药物安全。
病例2
王某某,女,28岁,因面部丘疹,脓疱,囊肿,结节反复十年余于2011年5月10日前来就诊。病史,患者十年前面部油腻出现丘疹,脓疱后逐年加重,曾自购药物治疗效果不佳,去美容院做过护理,美容,果酸,等祛痘处理,效果仍然不佳。后又去县医院皮肤专科治疗四月余,曾一度缓解数月,后又复发如前,近两年来病情加重伴结节形成。由于患者年青,病久不愈,恐面部留疤,心理备受折磨,精神压抑,慕名前来就诊,症见患者情绪低落,低头少语,面色暗红,皮肤色素部分沉着,面颊额部,鼻翼周围长有大量丘疹,粉刺,脓疱,结节,高出皮肤,触之压痛,痘印痘坑等疤痕形成。
经诊断为重度痤疮,采用实施例2所制备的治疗痤疮的丸剂治疗,早晚服用一次。预定3个疗程,每月为一疗程。嘱其服药期间不宜备孕,停药3个月后可正常怀孕,避免阳光及紫外线直射。
6月10日复诊,患者面部油腻减轻,丘疹减少,颗粒变小,脓疱稍小,颜色稍变淡,囊肿结节如前,病有好转,患者心情稍好,各项实验指标正常,继续下一疗程用药。
7月10日复诊,丘疹己消失80%,已无明显黑头,白头,粉刺,脓栓,脓疱消失50%,且直径缩小,囊肿体积缩小变硬,小囊肿已消失,面部皮肤色素沉着如前,皮肤干燥脱屑,唇仍干裂脱皮,不痛不痒,但能忍受。面部留有部分痘印。心电图,血常规,肌酸激酶,肝肾功能无异常发现,续用下疗程。
8年10月复诊,面部丘疹,脓疱消失,囊肿消失,皮肤色素沉着变淡,面部皮肤及嘴唇已无干燥脱皮,复查心电图,血常规,肌酸激酶,肝肾等功能均正常,本病己基本康复。
3年后随访,面部除留下少部分痘印外,面部,颈胸背部末见皮疹,皮色恢复正常,至今未再复发。
病例3
林某某,男42岁,患者因面部丘疹,脓疱,反复2年,加重3月,于2008年4月8日前来就诊,患者2年前散发面部丘疹,每于过食辛辣刺激或阳光直晒后加重或增多,时而减轻,并未治疗,但近3月加重,伴脓疱出现,且丘疹,黑头,白头上覆脓栓,部分经手挤压后局部红肿疼痛明显,故前来就诊。
经诊断为轻中度痤疮,采用实施例3制备的治疗痤疮的粉剂治疗一个月,早晚更服用一次。嘱其服药期间忌酒,阳光及紫外线直射。
5月8日复诊,面部丘疹完全消失,脓疱己消失90%,面唇干燥脱屑,血常规,心电图,肝肾功能无异,效不更方,续用下一疗程以期巩固,而后停药。
6月8日随诊,面部丘疹,脓疱消失,面唇己无干燥脱屑,临床痊愈,并与5年后随诊无复发。
病例4
刘某某,男21岁,因面部丘疹脓疱反复一年,加重3月,于2011年7月6日前来就诊。患者在校大学生,一年前无任何原因出现面部丘疹,时而缓解,间断内服药及外擦药,疗效不佳。近三月因经常熬夜,上网,辛辣饮食加重而就诊,就诊时面部油腻,前额,鼻翼周围满布丘疹,粉刺,间夹脓疱,色鲜而红,不痒偶痛。头颈胸背未见皮疹。
经诊断为痤疮,采用实施例4制备的治疗痤疮的片剂治疗。早晚各服一次,疗程一个月,一疗程后复诊,嘱服药期间避免阳光及紫外线直射,禁饮酒。
8月6日复诊,患者血常规,心电图,肝肾功能无异常发现,面部皮肤不油腻而干燥,稍有面唇脱屑,丘疹,粉刺,脓疱消失,本病因属轻症,一疗程告愈,嘱观察3月。2年后随访,至今未见复发。
病例5
郭某某,男,50岁,面丘疹,脓疱,结节十年余,痘印痘坑3年余,于2010年6月4日就诊,十年前无明显诱因出现面部,头皮,胸背散在丘疹,未在意,后继续增多,伴发白头,黑头,粉刺及脓疮,其后开始间断服用中西药物,疗效不佳,后转入某医院皮肤专科治疗四个月,曾一度缓解半年,后又反复发作,时而缓解,时而加重,患者对多种治疗己失去信心,放弃治疗。现病史,患者面部油腻,色素沉着,前额,鼻翼,唇周胸背满布丘疹,白头,黑头粉刺,夹杂大量脓疱,部分红肿疼痛,结节形成,遗留部分痘印疤痕,
经诊断为痤疮,采用实施例5制备的治疗痤疮的口服溶液治疗4个月,早晚用药一次,服药期间不宜日光及紫外线直晒,禁饮酒,可能面部口唇会出现脱屑,属正常药物反应,停药后很快恢复,不必担忧。
8月4日复诊,患者面部己无油腻,而现干燥,唇干脱皮,色素沉着己有恢复,头面部胸背等部丘疹渐少,白头,黑头粉刺消失,脓疱数量减少,直径缩小,部分消失,己无疼痛,痘印仍见,心电图,肌酸激酶,血常规,肝肾功能均无异常,疗效已显,效不更方,续用原方二月,医嘱其注意事项同前。
10月4日复诊,患者面唇干燥脱屑,面部色素沉着己恢复,面部,头皮,胸背丘疹,脓疱结节消失,惟痘印仍存,血常规,心电图,肌酸激酶,肝肾功能均无异常,治疗己趋康复,停用口服药,为巩固疗效,避免复发,过氧苯甲酸凝胶外擦,每天早晨一次,他扎罗汀乳膏每晚外擦一次,保持3个月。
患者3年后随访,头面,胸背等部己无痘疹,脓疱,结节,面部色素沉着己恢复,肤色正常。惟部分痘印残存,本病临床基本告愈。
病例6
杨某某,女,28岁,因面部丘疹,脓疱,结节,囊肿反复五年,加重三月并发部分痘印形成,于2009年4月7日就诊。
既往史,患者五年前面部前额,鼻翼,两颊偶发丘疹并未在意,后逐渐增多伴粉刺,白头,黑头,部分脓疱形成,故开始用药,曾用过多种中药,西药,外擦药,药名不详,疗效不佳,其间曾去过专业祛痘美容店,花费不少,当时有效,后又反复,近三月来逐渐加重伴囊肿,结节,部分痘印形成,据述患者父亲也有类似病症。
现病史,患者面部稍油腻,前额,两颊,鼻翼,唇周满布暗红色丘疹,白头,黑头,脓疱,部分囊肿,结节痘印形成
经诊断为痤疮,采用实施例6所制备的治疗痤疮的凝胶剂和实施例2所制备的治疗痤疮的丸剂进行治疗2个月,早晚分别用药1次。嘱患者服药期间不宜备孕,停药3月后方可怀孕,不宜阳光及紫外线直射,一月后查验血常规,心电图,肌酸激酶,肝肾功能,告之患者可能出现面部唇干燥脱屑,属正常药物治疗反应,随着停药以后很快恢复,期间如有其它身体不适及时就医。
6月7日复诊,面部己无油腻,面唇而显干燥脱屑,丘疹黑头粉刺消失,脓疱大为减少,体积较前缩小,唯囊肿,结节痘印未除,心电图,血常规,肝肾功能无异常,效不更方,为巩固效果,继续采用原治疗方案二个月,医嘱及其注意事项同前。
8月7日复诊,面唇部干燥脱屑,丘疹,脓疱,结节囊肿消失,残留部分痘印。心电图,血常规,肌酸激酶,肝肾功能无异常。随访3年,除原来残留痘印外未见其它痘疹复发。
最后说明的是,以上实施例仅用以说明本发明的技术方案而非限制,尽管参照较佳实施例对本发明进行了详细说明,本领域的普通技术人员应当理解,可以对本发明的技术方案进行修改或者等同替换,而不脱离本发明技术方案的宗旨和范围,其均应涵盖在本发明的权利要求范围当中。
Claims (10)
1.一种治疗痤疮的组合物,其特征在于,按照重量计算含有以下组份:异维A酸10-30份、红霉素110-125份、维生素B6 10-30份、葡萄糖酸锌60-80份。
2.根据权利要求1所述的治疗痤疮的组合物,其特征在于,按照重量计算由以下组份组成:异维A酸10-30份、红霉素110-125份、维生素B6 10-30份、葡萄糖酸锌60-80份、水牛角浓缩粉40-50份、连翘130-140份、青黛40-50份、黄连10-15份、炒牛蒡子110-120份、玄参130-140份、地黄100-120份、桔梗100-120份、芒硝10-15份、赤芍100-120份、甘草130-140份。
3.根据权利要求1所述的治疗痤疮的组合物,其特征在于,按照重量计算由以下组份组成:异维A酸10-30份、红霉素110-125份、维生素B6 10-30份、葡萄糖酸锌60-80份、茵陈120-140份,水牛角粉100-120份,生地100-120份,丹皮100-110份,玄参80-90份,黄连60-80份,金银花80-90份,芦荟20-30份,蝉蜕40-50份,当归60-80份,红花40-50份,白芷80-90份,白芥子40-50份、珍珠80-90份。
4.根据权利要求2所述的治疗痤疮的组合物,其特征在于,按照重量计算由以下组份组成:异维A酸20-30份、红霉素120-125份、维生素B6 20-30份、葡萄糖酸锌65-75份、水牛角浓缩粉40-45份、连翘130-135份、青黛40-45份、黄连12-15份、炒牛蒡子110-115份、玄参130-135份、地黄100-110份、桔梗110-120份、芒硝12-15份、赤芍110-120份、甘草130-135份。
5.根据权利要求3所述的治疗痤疮的组合物,其特征在于,按照重量计算由以下组份组成:异维A酸20-30份、红霉素120-125份、维生素B6 20-30份、葡萄糖酸锌65-75份、茵陈130-140份,水牛角粉110-120份,生地110-120份,丹皮100-105份,玄参85-90份,黄连60-70份,金银花85-90份,芦荟25-30份,蝉蜕45-50份,当归60-70份,红花45-50份,白芷85-90份,白芥子45-50份、珍珠85-90份。
6.根据权利要求4所述的治疗痤疮的组合物,其特征在于,按照重量计算由以下组份组成:异维A酸20份、红霉素125份、维生素B6 20份、葡萄糖酸锌70份、水牛角浓缩粉45份、连翘135份、青黛45份、黄连12份、炒牛蒡子115份、玄参135份、地黄110份、桔梗116份、芒硝12份、赤芍116份、甘草135份。
7.根据权利要求5所述的治疗痤疮的组合物,其特征在于,按照重量计算由以下组份组成:异维A酸20份、红霉素125份、维生素B6 20份、葡萄糖酸锌70份、茵陈135份,水牛角粉111份,生地111份,丹皮101份,玄参85份,黄连67份,金银花85份,芦荟25份,蝉蜕45份,当归67份,红花45份,白芷85份,白芥子45份、珍珠85份。
8.权利要求1-7任意一项所述的治疗痤疮的组合物在制备治疗痤疮药物中的应用。
9.根据权利要求8所述的应用,其特征在于,所述治疗痤疮药物可以为任意药学可接受剂型。
10.根据权利要求9所述的应用,其特征在于,所述治疗痤疮药物还包括药学可接受载体和/或助剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811426391.8A CN109172722A (zh) | 2018-11-27 | 2018-11-27 | 一种治疗痤疮的组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811426391.8A CN109172722A (zh) | 2018-11-27 | 2018-11-27 | 一种治疗痤疮的组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109172722A true CN109172722A (zh) | 2019-01-11 |
Family
ID=64938338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811426391.8A Pending CN109172722A (zh) | 2018-11-27 | 2018-11-27 | 一种治疗痤疮的组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109172722A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10252281B2 (en) | 2014-11-19 | 2019-04-09 | Jiangsu University | Jet type spray head double-limiting reversing mechanism |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1343517A (zh) * | 2001-09-20 | 2002-04-10 | 单友琴 | 治疗皮肤病的药物及其制备方法 |
CN105687460A (zh) * | 2016-04-08 | 2016-06-22 | 于清 | 一种治疗痤疮的中药组合物 |
CN106075205A (zh) * | 2016-08-26 | 2016-11-09 | 张光光 | 一种治疗痤疮的中药配方 |
CN106163526A (zh) * | 2014-01-29 | 2016-11-23 | 维奥姆生物科学有限公司 | 抗性痤疮的治疗 |
-
2018
- 2018-11-27 CN CN201811426391.8A patent/CN109172722A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1343517A (zh) * | 2001-09-20 | 2002-04-10 | 单友琴 | 治疗皮肤病的药物及其制备方法 |
CN106163526A (zh) * | 2014-01-29 | 2016-11-23 | 维奥姆生物科学有限公司 | 抗性痤疮的治疗 |
CN105687460A (zh) * | 2016-04-08 | 2016-06-22 | 于清 | 一种治疗痤疮的中药组合物 |
CN106075205A (zh) * | 2016-08-26 | 2016-11-09 | 张光光 | 一种治疗痤疮的中药配方 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10252281B2 (en) | 2014-11-19 | 2019-04-09 | Jiangsu University | Jet type spray head double-limiting reversing mechanism |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103341145B (zh) | 一种治疗银屑病的中药及其制备方法 | |
CN100546627C (zh) | 一种外用祛除黄褐斑的中药面膜 | |
CN109172722A (zh) | 一种治疗痤疮的组合物及其应用 | |
CN107468798A (zh) | 一种治疗痤疮的组合物及其制备方法和应用 | |
CN104740320A (zh) | 一种治疗痤疮的中药组合物及其制备方法 | |
CN104367906A (zh) | 一种治疗烧伤烫伤、酒糟鼻及痤疮的药物及其制备方法 | |
CN101129788A (zh) | 一种外用祛除黄褐斑的中药 | |
CN104352944B (zh) | 一种用于痤疮的药物组合物 | |
CN101940624B (zh) | 治疗白癜风的中药洗药 | |
CN104474405A (zh) | 一种治疗黄褐斑的中药组合物 | |
CN106074994B (zh) | 一种治疗银屑病的外用药物 | |
CN116211985B (zh) | 一种治疗扁平疣的中药组合物、中药制剂及其应用 | |
CN109865017A (zh) | 一种使用便利的治疗痤疮的膏剂及其制备方法 | |
CN104784311B (zh) | 用于防治动物口疮蹄癀的组合药物及其制备方法 | |
CN108144038A (zh) | 一种祛除黄褐斑的中药组合物及其应用 | |
CN110170020B (zh) | 一种养颜消斑中药面膜 | |
CN103127379A (zh) | 一种治疗雀斑的口服液 | |
CN101940695B (zh) | 治疗白癜风的中药药膏及其制备方法 | |
CN107233406A (zh) | 一种治疗激素脸的外用中药制剂 | |
CN106038913B (zh) | 一种治疗妇科宫颈炎的中药组合物及其应用 | |
CN105943584A (zh) | 一种治疗口腔溃疡的药物 | |
CN104173545B (zh) | 脂溢性皮炎外用搓涂酒剂及制备方法 | |
CN105343816A (zh) | 一种孕妇用口腔溃疡喷剂及其制备方法 | |
CN110302299A (zh) | 一种治疗宫颈癌的中药组合物及其制备方法 | |
CN104306811B (zh) | 一种治疗儿童寻常型银屑病的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190111 |
|
RJ01 | Rejection of invention patent application after publication |